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Highlights
• We introduce a novel method, based on a neural network (DeepSCAN), for
detecting lesion change in longitudinal MRI imaging in multiple sclerosis.
• The method had a sensitivity of 1.00 and a positive predictive value of
0.59 for detecting lesion load change, and an AUC of 0.999, when assessed
on twenty-six MS patients with longitudinal imaging.
• This compares to a sensitivity of 0.69 and a PPV of 0.18 when lesion
volume, as measured by our classifier, was used to assess lesion load change
(AUC = 0.71)
• Change in lesion count (another commonly used metric) had a sensitivity
of 0.57 and a PPV of 0.38 (AUC = 0.51).
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Abstract
The detection of new or enlarged white-matter lesions is a vital task in the moni-
toring of patients undergoing disease-modifying treatment for multiple sclerosis.
However, the definition of ‘new or enlarged’ is not fixed, and it is known that
lesion-counting is highly subjective, with high degree of inter- and intra-rater
variability. Automated methods for lesion quantification, if accurate enough,
hold the potential to make the detection of new and enlarged lesions consis-
tent and repeatable. However, the majority of lesion segmentation algorithms
are not evaluated for their ability to separate radiologically progressive from
radiologically stable patients, despite this being a pressing clinical use-case. In
this paper, we explore the ability of a deep learning segmentation classifier to
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separate stable from progressive patients by lesion volume and lesion count,
and find that neither measure provides a good separation.. Instead, we pro-
pose a method for identifying lesion changes of high certainty, and establish on
an internal dataset of longitudinal multiple sclerosis cases that this method is
able to separate progressive from stable time-points with a very high level of
discrimination (AUC = 0.999), while changes in lesion volume are much less
able to perform this separation (AUC = 0.71). Validation of the method on
two external datasets confirms that the method is able to generalize beyond the
setting in which it was trained, achieving an accuracies of 75 % and 85 % in
separating stable and progressive time-points.
Keywords: Deep Learning, Multiple Sclerosis, MRI, Longitudinal Imaging
1. Introduction
Magnetic resonance imaging is the most important imaging method for di-
agnosis and monitoring of multiple sclerosis. The 2017 revised Mcdonald diag-
nostic criteria for the diagnosis of multiple sclerosis require the dissemination of
lesions in both space and time. Lesion load change is also crucial for the assess-
ment of disease activity, since patients who are assigned with disease modifying
therapies and no evidence of disease activity (NEDA) harbor a better progno-
sis [1, 2, 3, 4]. Radiological progression can be separated into new or enlarged
lesions in T2 weighted imaging, and new enhancing lesions on T1 weighted imag-
ing with Gadolinium-based contrast agents (GBCA). While standard imaging
protocols for multiple sclerosis have included GBCA, there is increasing evidence
that high resolution 3D unenhanced MRI is sufficient to detect the presence of
new or enlarged lesions [5].
Detection of new and enlarged lesions in multiple sclerosis imaging by human
raters is time-consuming and limited by inter- and intra-rater variability [6]. As
a consequence, manual lesion volumetry and lesion counting has limited sen-
sitivity for new lesion detection. Delineation of new and enlarged lesions can
be improved by working on subtraction MRI, but this still requires substantial
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human user interaction and judgement, as well as manual intensity normaliza-
tion. A recent study showed that FLAIR subtraction MRI had a sensitivity of
80% for detecting new or enlarged lesions. [7]. Registration errors, flow artifacts
and lesion signal intensity differences can result in the detection of false-positive
lesions on subtraction images [8].
Several groups have proposed automated methods for multiple sclerosis le-
sion segmentation, mostly validated in a cross-sectional fashion. [9, 10, 11, 12]
Even where longitudinal data was used to assess the performance of classifiers,
consistency of segmentations over time, or the ability to detect new lesions were
not investigated [13]. Since MR contrast will differ between time-points, even on
the same scanner, and since the borders of MS lesions are often not well defined,
automated methods will typically show small differences in the boundaries of
lesions at different time-points, even if no lesion growth has taken place. Since
even the best automated methods also make false positive and false negative
lesion identifications, lesion counts may also not be reliable in a longitudinal
setting. Several researchers have proposed methods to harmonize segmenta-
tions across two or more time-points. Jain et al propose a joint expectation-
maximization (EM) framework for two time-point white matter (WM) lesion
segmentation, and the Lesion Segmentation Toolkit, a tool integrated in SPM,
has a longitudinal pipeline which adapts existing segmentations across multi-
ple time-points [14, 15]. Meanwhile, Salem et al proposed a logistic regression
classifier for detected new and enlarged lesions showing ”considerable growth”
using features derived from subtraction imaging and deformation fields derived
from registration of two time-points.[16]
In a companion paper, we have introduced a novel method (DeepSCAN MS)
based on convolutional neural networks (CNNs), for multiple sclerosis lesion seg-
mentation, which we demonstrated to outperform previous methods.[17] In this
paper, we demonstrate that changes in lesion count and volume change, esti-
mated using our method, do not perform well as a method for separating stable
and progressive MS cases. Simultaneous lesion growth and lesion resolution may
occur at a single time-point, which will not be apparent from simply observing
4
         
volume changes. Further, variations in image contrast between acquisitions can
lead to substantial volumetric changes in automated lesion delineation, even
when using ‘state-of-the-art’ classification methods. Lesion counts are also only
approximate measures of activity, since lesions may be missed or underseg-
mented, false positives may give the impression of lesion growth where none
exists, and lesions may become confluent, leading to an increase in lesion tissue
but a decrease in lesion count.
As a potential solution to this issue, we instead propose to identify new and
missing lesion tissue by using the confidence of an automated classifier in its
own segmentation. Measures of segmentation uncertainty have previously been
proposed as a method of rejecting false positive MS lesion identifications. [18] To
our knowledge, our method is the first to leverage segmentation confidence in the
detection of longitudinal change. Our recently introduced MS lesion classifier,
DeepSCAN, produces for each tissue map a ’label-flip probability’, which is a
measure of uncertainty derived from the training data. We use the segmentation
of the classifier and the label-flip map to distinguish between patients with no
new or enlarged lesions (those satisfying that component of the NEDA criteria)
and those with genuinely new or enlarged lesions. We identify as new lesion
tissue only those voxels that were confidently not present at time-point t=0 but
that are confidently lesion tissue at time-point t=1. The method requires T1,
FLAIR and T2 imaging adhering to modern best-practice imaging standards in
MS (specifically, a 3D FLAIR and 3D T1 acquisition), such as those specified
in the OFSEP minimal MRI protocol. [19].
2. Methods
In this paper, we study the ability of a previously trained deep learning
classifier to detect longitudinal changes in T2 lesion load, by several means:
lesion counting, overall lesion volume, detecting voxel-by-voxel change using
coregistration, detecting voxel-by-voxel confident change using a method which
incorporates classifier confidence. We describe the patient cohorts, the deep
5
         
learning method, and the methods for detecting lesion growth. We utilise data
from three sources. The first are MRI datasets of patients with remitting-
relapsing multiple sclerosis that were identified from the MS cohort databank
of the University of Bern. Use of data for this study was approved by the
local ethics committee (Cantonal Ethics Commission Bern, Switzerland ’MS
segmentation disease monitoring’, approval number 2016-02035) and all patients
gave general consent for data storage and analysis of their MRI datasets. This
data was from the same centre and scanner as that used for the training of our
fully convolutional deep learning classifier (DeepSCAN).
Additional anonymized datasets were provided by Radiology Center Bethanien,
(which we subsequently refer to as the Zurich dataset), and from the Klinikum
Rechts der Isar, Munich, Germany (which we subsequently refer to as the Mu-
nich dataset).
2.1. Patient cohorts and MR imaging
Patients from the Bernese MS cohort were included in the Bern dataset if
they had at least three consecutive MRI datasets, and were not among the 50
casesused in training of the DeepSCAN classifier. [17] All patients fulfilled the
revised McDonald criteria of 2010 for relapsing-remitting multiple sclerosis.[20]
MR images from the Bern dataset were acquired on a 3T MRI (Siemens
Verio, Siemens, Erlangen, Germany) . The protocol settings were i) T1 weighted
MP-RAGE pre- and post gadobutrol i.v. (TR 2530 ms, TE 2.96 ms, averages
1, FoV read 250 mm, FoV phase 87.5 % voxel size 1.0 x 1.0 x 1.0 mm, flip angle
7, acquisition time 4:30 min. slices per slab 160, slice thickness of 1.0 mm) ii)
T2- weighted imaging (TR 6580 ms, TE 85 ms, averages 2, FoV read 220 mm,
FoV phase 87.5 %, voxel size 0.7 x 0.4 x 3.0 mm, flip angle 150, acquisition time
6:03 min, 42 parallel images were acquired with a slice thickness of 3.0 mm,)
iii) 3D FLAIR imaging (TR 5000 ms, TE 395 ms, averages 1, FoV read 250
mm, FoV phase 100 %, voxel size 1.0 x 1.0 x 1.0 mm, acquisition time 6:27 min.
A total of 176 parallel images were acquired with a slice thickness of 1.0 mm).
All patients received Gadobutrol (Gadovist) 0.1 ml/kg bodyweight immediately
6
         
after the acquisition of the unenhanced T1w sequence.
MR images from the Zurich dataset were acquired using a standardized ac-
quisition protocol on a 3T MRI (Siemens Skyra, Siemens, Erlangen, Germany),
including: i) T1 weighted MP-RAGE precontrast (TR 2300 ms, TE 2.9 ms, TI
900 ms, averages 1, FoV read 250 mm, FoV phase 93.75 % voxel size 1.0 x 1.0
x 1.0 mm, flip angle 9, acquisition time 05:12 min. ) ii) T2- weighted imaging
(TR 4790 ms, TE 100 ms, averages 1, FoV read 220 mm, FoV phase 100 %,
voxel size 0.7 x 0.4 x 3.0 mm, flip angle 150, acquisition time 02:16 min iii) 3D
FLAIR imaging (TR 5000 ms, TE 398 ms, TI 1800 ms, averages 1, FoV read 250
mm, FoV phase 100 %, voxel size 1.0 x 1.0 x 1.0 mm, flip angle 120, acquisition
time 04:17 min. ).
MR images from the Munich dataset were acquired with a 3T MRI (Achieva;
Philips Healthcare, Best, the Netherlands) including: i) 3D T1 gradient-echo
imaging, performed before and at least 5 minutes after administration of 0.1
mmol/kg gadolinium-based contrast material : voxel size 1.0 x 1.0 x 1.0 mm;
acquisition time, 6 minutes ii) a three-dimensional fluid-attenuated inversion-
recovery (FLAIR) sequence, voxel size, 1.03 x 1.03 x 1.5 mm3; acquisition time,
5 minutes iii) T2-weighted imaging: voxel size, 1.03 1.03 1.5 mm; TR 40006000
ms (variable); TE 35 ms; acquisition time 5 min.
2.2. The DeepSCAN MS lesion classifier
In a previous paper on brain tumor segmentation [21] , we proposed a hy-
brid of U-net [22] and Densenet [23], in which the bottleneck layer of the Unet
is a single dense block, and in which some of the pooling and upscaling is re-
placed by dilated convolutions. In a subsequent paper, we introduced a new
loss function (label-flip loss), in which the probability that classification output
differs from the ground truth used for supervision is used to anneal gradients
coming uncertain datapoints, and demonstrated that this loss function leads to
improved results in brain segmentation.[24]. In a companion paper to this pa-
per, we trained a classifier, which we call DeepSCAN MS, on fifty cases from the
Bernese MS cohort databank [17]. In this section, we first summarize the proce-
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dure for training the DeepSCAN MS classifier, and then describe its application
in detecting longitudinal changes in MS.
1 2 4 8
n
Key
3D convolutional block, 
padding (0,1,1)
2D upsampling/skip block, 
1 by 1 conv
2D downsampling 
block (maxpooling)
3*5*196*196
32 32 32
32*98*98
+72 +72 +72 +72
36 * 196* 196
2D dilated dense block,
(6 dense units, Dilation factor n) 
BN
Conv, 12 filters
ReLu
Concat
M features
M + 12 features
Dense unit
320*98*98
Figure 1: The DeepSCAN architecture used in this paper for lesion and brain-structure seg-
mentation
The DeepSCAN MS classifier is shown in Figure 1: it is a fully-convolutional
neural network trained on fifty cases from the Bernese MS cohort databank,
which provides segmentations of white-matter lesions, together with segmenta-
tions of the cerebellum, subcortical grey matter structures, and cortical grey and
white matter, in MS patients. (In this study we only use the lesion segmenta-
tions produced by the classifier.) The network was trained using a combination
of focal loss and our previously defined label-flip loss, on lesion labels provided
by manual raters, and brain anatomy labels provided by Freesurfer. In label flip
loss, for each voxel, and tissue class, the network outputs two probabilities: the
probability p that voxel contains the tissue class, and the probability q that the
label predicted does not correspond to the label in the ground-truth annotation
(i.e., the probability of a ’label flip’). IF BCE stands for the standard binary
cross-entropy loss, and y is the target label, then the label-uncertainty loss is:
BCE(p, (1− x) ∗ q + x ∗ (1− q)) + BCE(q, z) (1)
where
z = (p > 0.5) ∗ (1− x) + (p < 0.5) ∗ x (2)
If q is close to zero, and the label is correct, the first term is approximately
8
         
the ordinary BCE loss: if q is close to 0.5 (representing total uncertainty as to
the correct label) the first term tends to zero. This loss therefore attenuates
loss in areas of high uncertainty (i.e., where the network is likely to disagree
with the ground truth) during training, and indicates areas where segmentation
reliability may be poor when applied to new data.
On an internal dataset of 32 patients, the DeepSCAN classifier achieved a
mean Dice coefficient of 0.60 versus a manual consensus ground truth for the task
of segmenting MS lesions, compared to a mean Dice coefficient of 0.58 between
two independent manual raters. This result was sustained when we examined
external data from the MSSEG challenge [25]. This dataset consists of fifteen
cases, from two centres and three scanners, each rated by seven independent
manual raters. Imaging quality is of a similar standard to that used in the
Bernese MS cohort. [19]. Versus the independent raters, mean Dice coefficient
with the output of DeepSCAN (without retraining on the external data) ranged
between 0.56 and 0.61. For comparison, the mean Dice coefficient between the
MSSEG raters on the training data ranged between 0.54 and 0.75.
As we have already discussed, manual segmentations of MS lesions have
large inter- and intra-rater variability, and so we must accept that this ’ground-
truth’ may, for lesion segmentation, contain many inconsistencies: missed or
under-segmented lesions, and false identifications or over-segmented lesions. For
example, a retrospective analysis of the 32 manual lesion segmentations used to
validate the DeepSCAN classifier found an average of 18 false positive lesions
and 4 missed lesions per subject.
For full details of the training and validation of the DeepSCAN MS classifier,
please see McKinley et. al [17].
2.3. Dichotomization of imaging data: progressive vs stable
For each patient and each time-point, a decision was made by an experienced
neuroradiologist if that time-point represented, from an imaging standpoint,
progressive disease (PD, if any new FLAIR- or contrast-enhancing lesions was
detected) or stable disease (SD, if the number of lesions remained stable or
9
         
reduced over time) ,based on visual analysis by one of the authors (LG for cases
from Bern, CW for cases from Zurich, PE for cases from Munich). In each case,
the full clinical sequence (including T1 post-contrast for all sites, and Double
Inversion Recovery for Munich) was included in the analysis.
2.4. Automated Segmentation by DeepSCAN convolutional neural network
For each patient and time-point we used the DeepSCAN classifier to generate
lesion masks and label-flip maps for MS lesions lesions, using the T1-weighted,
T2-weighted, and T2 FLAIR imaging as input. To aid in comparison between
time-points, these maps were resampled to 1mm3 isotropic resolution. The
classifier also returns a 1mm3 isotropic skull-stripped FLAIR image in the same
space as the lesion and label-flip maps.
2.5. Coregistration
In order to compare cases across time-points, it was necessary to register
all imaging for each patient to a common space. To avoid biases inherent in
registering to a particular time-point, we applied a robust registration technique
(the Robust Template method from Freesurfer) to the skull-stripped FLAIR
images produced by our CNN tool, in which all time-points are registered to
a common patient-specific template . [26] After construction of the template,
lesion masks and lesion confidence maps were rigidly registered to the template
space using the transforms output by the robust template method.
2.6. Lesion change detection by classification uncertainty
We describe here the decision procedure for labelling a voxel as ’new lesion’,
given lesion mask and label-flip maps at time-points A and B in a common,
coregistered space, and a threshold q determining acceptable confidence. For
each time-point, a voxel is labelled as ’confident lesion’ if it is in the lesion mask,
and if the label-flip probability is less than q. A voxel is labelled ’confident non-
lesion’ if it is not in the lesion mask, and if the label-flip probability is less
than q. A voxel is labelled as ’new lesion’ at time-point B, if it is labelled as
10
         
’confident non-lesion’ at time-point A, and ’confident lesion’ at time-point B. It
is labelled ’missing lesion’ at time-point B, if it is labelled as ’confident lesion’
at time-point A, and ’confident non-lesion’ at time-point B. Finally, connected
components of the ’new lesion’ and ’missing lesion’ maps were calculated.
We subsequently identified all connected components of ”new lesion” tissue.
To improve robustness to coregistration artifacts, all connected components of
the new lesion map containing fewer than 12 voxels were deleted.
For the purposes of our initial investigation, we set the value of q to be 0.05:
i.e., we determine a voxel to be classified with confidence if the model predicts
a 5% or lower chance of the predicted label disagreeing with the manual rater.
2.7. Lesion change detection by threshold margin
A more simplistic methodology for labelling lesions as confidently or uncer-
tainly classified is to set a margin around the ordinary decision threshold, 0.5,
and to label all voxels outside of this margin as ’confident’. This method has
the advantage that it may be applied to classifiers which do not output a label-
flip probability: however, in general the output of modern neural networks is
not well calibrated: the scores output by deep networks do not correspond to
observed probabilities and are typically overconfident [27].
Concretely, we set a margin 0 < m < 0.5, and classify every voxel with
p < 0.5 − m as confident nonlesion, while every voxel with p > m + 0.5 is
classified as confident lesion. The measure of new lesion tissue is then as above:
a voxel is new lesion if it is labelled as ’confident lesion’ at time-point A, and
’confident non-lesion’ at time-point B. As above, connected components below
12 voxels were deleted.
For the purposes of our initial investigation, we set the value of m to be
0.45: i.e., we determine a voxel to be classified as confident lesion if the model
predicts a score of .95 or greater and to be classified as confident non-lesion if
the model predicts a score of 0.05 or less.
11
         
2.8. Evaluation
We compared our proposed methods to four other methods on our internal
(Bernese) test set: absolute change in lesion volume, relative change in lesion
volume, change in lesion count, and total new lesion volume (equivalent to our
method with q = 0.5). To test the power of these measures to separate pro-
gressive and stable time-points, we plotted the receiver-operating characteristic
(ROC) curves for each of the above methods. While ROC-AUC analysis gauges
the ability of a metric to separate positive and negative examples across all
operating thresholds, clinical applicability required that a particular threshold
is chosen. .We therefore tested the performance of our metrics at an operat-
ing threshold corresponding to ‘no lesion change’ (i.e. lesion count > 0, lesion
volume change > 0, and new lesion volume > 0).
We assessed the sensitivity of our method to its parameters, by comparing
the ROC curves of the method at different values of uncertainty threshold q,
margin m, and small-growth threshold.
3. Results
Twenty-six patients from the Bernese MS databank satisfied the inclusion
criteria, of which 16 were judged from radiological reports to have no lesion
changes in any of the time-points, and so were labelled as having stable disease
(SD). The remaining 10 cases were judged to have progressive disease (PD).
The mean number of time-points per patient was 4.4 for the progressive pa-
tients, and 4.9 for the stable patients. Among the ten progressive patients,
there were a total of 13 time-points where the radiological reports indicated
progression, meaning that approximately 30% of the time-points in those pa-
tients showed lesion progression. Mean time between examinations for 223 days,
with a standard deviation of 98 days.
3.1. ROC-AUC analysis
For each proposed method, we computed the area under the receiver-operating
characteristic for the bernese dataset: see Figure 2. Lesion counting performed
12
         
TN FP FN TP Accuracy Sensitivity PPV FPR
Confidence method> 0 74 9 0 13 0.91 1.00 0.59 0.11
Margin method > 0 83 0 6 7 0.94 0.54 1.00 0.00
New lesion volume > 0 8 75 0 13 0.22 1.00 0.15 0.90
Volume change> 0 41 42 4 9 0.52 0.69 0.18 0.51
Lesion count change > 0 50 33 8 5 0.57 0.38 0.13 0.40
Table 1: Ability to distinguish progressive vs stable MS at thresholds corresponding to no
lesion change, on internal test set, showing the number of true negatives (TN), false positives
(FP), false negatives (FN) and true positives (TP), together with accuracy, positive predic-
tive value and recall. Metrics are shown for the label-flip method (Confidence method) and
the margin-based method (Margin method), together with new lesion volume, lesion volume
change and lesion count change.
worst, with a ROC-AUC of 0.51, while absolute and relative volume change
performed comparably, with ROC-AUCs of 0.70 and 0.71 respectively. The
proposed method using score margins had an AUC of 0.77. Meanwhile, the
proposed method using network-derived uncertainty had a ROC-AUC of 0.999.
3.2. Performance at meaningful thresholds
Results of this analysis are shown in Table 1.
For lesion counting, this metric leads to a total of 33 time-points being iden-
tified as progressive, when in fact they were stable according to radiological
reports. For lesion volumetry, 42 time-points were falsely identified as being
stable. For the proposed method, nine stable time-points were labelled as pro-
gressive. Meanwhile, the proposed method based on uncertainty successfully
identified all progressive time-points. By comparison, the lesion volume metric
failed to find four of the progressive time-points, and lesion counting failed to
find eight progressive time-points. The proposed method based on a margin
around the decision boundary made no false positive identifications, but failed
to find six of the progressive time-points.
13
         
Figure 2: Receiver operating curves for the detection of lesion progression using DeepSCAN,
on our internal validation set, via absolute lesion volume change (AUC=0.70), relative volume
change (AUC = 0.71), lesion count change (AUC = 0.51), the proposed method using a score
margin of .45 (AUC=0.77) and the proposed method using an uncertainty threshold of 0.05
(AUC ≈ 1). The star on each curve represents a cutoff where the patient is labelled as stable
if the considered metric is less than or equal to zero.
.
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3.3. Sensitivity to uncertainty threshold, score-margin and small-growth thresh-
old
The best-performing method according to area under the ROC curve, ac-
cording to our initial analysis, was achieved using our uncertainty-based method
with an uncertainty threshold of 0.05: i.e. voxels which had a flip-probability
greater than 0.05 at either time-point are not used to calculate lesion change. At
a fixed operating threshold, meanwhile, our two proposed methods performed
similarly in terms of accuracy, but the method derived from label-flip confidence
had perfect sensitivity and lower PPV, while the method derived from a margin
around the threshold had perfect PPV and lower sensitivity.
Both of these methods rely on a parameter which can be varied, with an
effect on the performance. In this section we investigate the effect of changing
those parameters.
3.3.1. Effect of changing uncertainty threshold
For uncertainty threshold values lower than the one we initially selected
(0.0005, 0.001 and 0.01), the AUC was slightly reduced, at 0.92. At larger
uncertainty thresholds than initially selected, the AUC was also slightly lower:
a threshold of 0.1 gave an AUC of 0.99, and a threshold of 0.2 gave an AUC of
0.96.
3.3.2. Effect of changing classification margin
The effect of changing the classification margin was much more drastic. By
setting a narrower classification margin (0.15), we were able to achieve an AUC
close to the performance of the uncertainty-based method (AUC = 0.998). A
slightly larger margin of 0.2 gave worse performance (AUC = 0.96), while a
slightly narrower margin of 0.1 led to a smaller decrease in performance (AUC
= 0.996).
3.3.3. Effect of changing threshold for growth
In the method as described, areas of growth below 12 voxels do not count
towards lesion growth. The method is reasonably robust to changes in this
15
         
lesion-growth threshold. A larger threshold of 24 voxels led to an AUC of 0.96,
while a smaller threshold of 6 voxels led to an AUC of 0.997. Not applying a
threshold yielded an AUC of 0.98.
3.4. Performance on external data
Several authors have reported difficulties of automated methods for MS le-
sion segmentation to perform on out-of-sample data.[25, 11] In our previous
paper, we already validated that performance of the DeepSCAN MS classifier
is not substantially degraded when applied to data adhering to similar protocol
standards from different centres[17]. In this section, we report the ability of
the uncertainty-based method, as described above to identify progressive time-
points in external data. The method was applied to data from eight patients,
each having four consecutive time-points (thirty-two datsets, twenty-four after
baseline) from the Zurich dataset. This data was supplied full anonymized.
In a second test of generalization, the full lesion segmentation algorithm and
uncertainty-based method was containerized using Docker, and provided to the
co-authors from Munich (BW, CB, PE, MM), who applied the classifier to cases
from their centre.
The Zurich dataset consisted of four consecutive time-points (thirty-two
datasets, twenty-four after baseline imaging). Of the twenty-four follow-up
time-points, five were judged by the rater (CW) to have new or enlarged le-
sions. The proposed method successfully identified three of the five progressive
time-points (sensitivity of 60%) and labelled an additional three incorrectly as
being progressive. (PPV of 84 %), Overall accuracy on this dataset was 75 %
The Munich dataset consisted of 53 pairs of baseline and followup image,
of which 24 were judged progressive, and 29 judged stable. The method suc-
cessfully identified 16 of the 22 progressive time-points (Sensitivity of 72%) and
correctly identified all of the stable time-points. (PPV of 100 %) Overall accu-
racy on this dataset was 85%
16
         
Accuracy Sensitivity PPV
Zurich 0.75 0.60 0.84
Munich 0.85 0.72 1.00
Bern 0.91 1.00 0.59
Table 2: Performance of the confidence-based method on the three datasets studied in this
paper, showing Accuracy, Sensitivity, and Positive Predicative Value (PPV)
4. Discussion
MRI is the method of choice to determine lesion load evolution in patients
with multiple sclerosis. The accurate detection of new or enlarged white-matter
lesions in multiple sclerosis patients is a pivotal task of the disease monitor-
ing process in patients who receive disease-modifying treatment. However, the
definition of ’new or enlarged’ remains ill-defined, and lesion counting remains
subjective with a considerable degree of inter- and intra-rater variability depend-
ing on the level of experience of the reporting expert. Automated methods for
lesion quantification, if accurate, hold the potential to make the detection of new
and grown lesions consistent and repeatable. Until now, the majority of lesion
segmentation algorithms are not well evaluated for their ability to accurately
separate radiologically progressive disease course from radiologically stable pa-
tients during follow-up. Despite this being the pressing clinical use-case and
information for the clinicians with impact on further treatment regime selection
for the MS patients. We demonstrate that measures of new lesion load derived
from label-flip uncertainty outperform lesion counting as well as absolute and
relative volume change detection in the longitudinal analysis of MS lesions. The
major advantage of the proposed approach is to identify the time-point during
follow-up where lesion progression was evident with a very high accuracy and
positive predictive value. The method is fully automated, and therefore offers
the benefit of being objective and independent from user bias, thus leading to
more trustful longitudinal evaluations.
The method developed relies on a minimum standard of MR imaging cor-
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responding to a modern MRI protocol for imaging of demyelinating disease: in
particular a 3D T1 and 3D FLAIR acquisition (with approximately 1mm3 or
better voxels). The recommended protocol is in keeping with the 2016 Con-
sortium of MS Centers Task Force recommendations and can be executed in
approximately 20 minutes. In particular, the method does not rely on the avail-
ability of a post-contrast T1 sequence: recent research suggests that modern 3D
imaging at 3T can reduce or eliminate the need for contrast-enhanced sequences.
[5, 7]
The method in this paper proposes to track changes in lesion load by lever-
aging measures of uncertainty in the location of lesion boundaries, based on
the predictions of a deep learning convolutional neural network classifier, Deep-
SCAN. This method has already been shown to perform well at lesion segmenta-
tion in a cross-sectional setting: the classifier was more than twice as effective in
lesion detection as both previous generations of CNN-based segmentation tools
and freely-available lesion segmentation SPM toolboxes. [17] In this paper, we
sought to demonstrate the same classifiers ability to detect lesion change: by
considering as new lesion tissue only those voxels which are classified confidently
by DeepSCAN, progressive time-points were detected with an accuracy of 0.91
and a recall of 1.0, when applied to data from the same centre as those used to
train the classifier. By comparison with standard metrics, such as lesion count
progression or volume changes, no progressive time-points were falsely identified
as stable, and the risk of false positive results decreased by more than a factor
of three, in comparison with lesion counting, and a factor of eight compared to
simply counting new lesion tissue voxels. An alternative method, relying on a
margin around the decision boundary rather than uncertainty, performed simi-
larly to the label-flip confidence method, but only after the correct margin was
found. We therefore tend to prefer the uncertainty-based method.
Furthermore, our method (trained on fifty cases from a single institution)
also performs well when applied to two datasets from external centres. While
detection of progression was perfect on the internal validation set, the method
failed to identify progression at two time-points in the Zurich dataset and eight
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time-points from the Munich data set. This was caused by small new lesions
which were correctly identified, but too small to be identified confidently. For
example, the two cases mislabelled as stable in the Zurich dataset each had
a single, small new lesion. In the first case this was a small faint lesion in
deep white matter, and in the second it was a small periventricular lesion.
In both cases these lesions were correctly segmented by DeepSCAN, but not
at a sufficient level of confidence to deem them confident new lesion tissue.
Representative slices from these two cases are shown in Figures 3 and 4. A
representative slice from a further case from the external dataset, showing two
correctly identified instances of lesion growth, is shown in Figure 5. We can
hope that detection of missed lesions can be improved by training on larger,
more diverse datasets, or by the inclusion of more sensitive sequences. In the
case of the Munich dataset, a Double Inversion Recovery sequence was used by
human raters in addition to FLAIR to identify lesions. Detection of lesions on
FLAIR only was shown in a recent study to miss 27.6 % of new or grown lesions,
compared to DIR.[5] It is therefore perhaps not surprising that some time-points
labelled as stable were judged as progressive by the human raters, as the new
lesions may not have been visible in the FLAIR sequence. This suggests that
it would be worthwhile to extend our approach to incorporate DIR imaging.
This would, however, limit the applicability of the technique in clinical practice.
Alternatively, the proposed method could be used by a reader, in conjunction
with segmentations from the separate time-points, to streamline semi-automatic
detection of new lesions.
Semi-automated methods for MS lesion segmentation provide a simple method
to assess the change in lesion load of an MS patient. Simple FLAIR image sub-
traction methods or background subtractions of binarized image have been used
to manually identify new lesion tissue with high accuracy and low error rates.
Other methods included graph cuts, i.e. graph-based segmentation techniques
that employ seed points set by the user and a cost function or active contour-
ing using prior information. These methods still require a degree of human
interaction, are time consuming and require an expert-in-the-loop. Currently,
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Figure 3: Two time-points from the external dataset, showing a missed new lesion. (A)
coregistered FLAIR, (B) lesion segmentations, (C) Label-flip maps. New lesion is correctly
detected by DeepSCAN at TP2 , but not labelled as confident new lesion. Small, faint lesions
are more likely to be labelled as uncertain than large, clear lesions.
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Figure 4: Two time-points from the external dataset, showing a missed new periventricular
lesion. (A) coregistered FLAIR, (B) lesion segmentations, (C) Label-flip maps. Lesion is
detected by DeepSCAN at TP2, but location of new lesion is uncertain at TP1. Owing to
the similar appearance of periventricular lesions and subependymal gliosis, label confidence is
typically low in this region.
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Figure 5: A case from the Zurich dataset. Top Row: FLAIR imaging at baseline and three
subsequent time-points. A: FLAIR images with lesion masks as provided by the DeepSCAN
classifier. B: FLAIR images with masks indicating naive lesion change (lesion is absent at
previous time-point but present at current time-point). time-points 3 and 4 show new lesion
tissue due to differences in imaging, rather than genuine lesion growth. C: Regions where
DeepSCAN flip probability > 0.05 highlighted in blue. D: Confident new lesion tissue maps
as provided by the method, showing correctly detected new lesion tissue at time-point 2, and
no change at time-points 3 and 4
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substantial effort is being invested in the development of fully-automated lesion
annotation methods, and results indicate that advances in model architecture
and training techniques, together with increasing availability of expert-labelled
data, have brought us close to, or even allow us to exceed, the performance
of expert human raters [25, 17]. However, in the study at hand, we could
demonstrate that despite the effectiveness of automated lesion segmentation,
automatically detected changes in lesion volume in MS patients alone is not a
sufficient method for performing separation between radiologically progressive
course from radiologically stable patients. Instead, we propose a method for
identifying lesion changes of high certainty. We conclude that, while solitary
lesion volume or total lesion load - together with clinical disease course / EDSS
of MS patients - are strong predictors of disease course across a reference MS
population, in the individual MS patient changes in these measures are not an
adequate means to clear differentiate progressive disease course from no disease
activity.
We believe that the performance shown by our method will encourage the
MS community to investigate its use in different clinical settings. The benefits
of automated methods lie not only in terms of the accuracy in differentiation of
progressive versus stable disease course on MR imaging but also in the related
reductions in time and economic costs derived from manual lesion labelling.
While there is an increasing level of evidence that CNNs are comparable to
human rater’s performance in cross-sectional studies, only longitudinal clinical
follow-up studies will demonstrate the utility of these methods for identifying
patients who remain stable under DMT.
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